Name: Ibrutinib: coming of age?
Creator: Jennifer R. Brown
Keywords: Adult, 03 medical and health sciences, Lymphoma, B-Cell, Pyrimidines, 0302 clinical medicine, Piperidines, Adenine, Humans, Pyrazoles, Leukemia, Lymphocytic, Chronic, B-Cell

descriptionPublicationkeyboard_double_arrow_right Article 26 Apr 2018 English Publisher:American Society of HematologyJournal:Blood, volume 131, pages 1,880-1,882 (issn: 0006-4971, eissn: 1528-0020,

Authors: Jennifer R. Brown;

doi: 10.1182/blood-2018-02-832071

pmid: 29699993

Ibrutinib: coming of age?

- Summary
- Subjects
- Metrics

Abstract

In this issue of Blood, O’Brien et al report long-term efficacy and safety of ibrutinib in the first cohort of patients with chronic lymphocytic leukemia (CLL) treated, now with 5-year follow-up, the longest of any CLL cohort to date.1

Related Organizations

Harvard University
United States
Dana-Farber Cancer Institute
United States

Keywords

Adult, Lymphoma, B-Cell, Pyrimidines, Piperidines, Adenine, Humans, Pyrazoles, Leukemia, Lymphocytic, Chronic, B-Cell

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average